Sanctuary Advisors LLC Takes Position in BioNTech SE (NASDAQ:BNTX)

Sanctuary Advisors LLC acquired a new position in BioNTech SE (NASDAQ:BNTX) in the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund acquired 2,558 shares of the company’s stock, valued at approximately $223,000.

Several other hedge funds and other institutional investors have also added to or reduced their stakes in the business. Covestor Ltd lifted its holdings in shares of BioNTech by 47.2% during the 1st quarter. Covestor Ltd now owns 415 shares of the company’s stock valued at $38,000 after buying an additional 133 shares during the period. GAMMA Investing LLC increased its position in BioNTech by 121.0% during the first quarter. GAMMA Investing LLC now owns 274 shares of the company’s stock valued at $25,000 after acquiring an additional 150 shares during the last quarter. Midwest Professional Planners LTD. lifted its holdings in BioNTech by 7.2% in the first quarter. Midwest Professional Planners LTD. now owns 3,177 shares of the company’s stock valued at $293,000 after acquiring an additional 212 shares during the period. BNP PARIBAS ASSET MANAGEMENT Holding S.A. lifted its holdings in BioNTech by 2.3% in the first quarter. BNP PARIBAS ASSET MANAGEMENT Holding S.A. now owns 9,800 shares of the company’s stock valued at $904,000 after acquiring an additional 223 shares during the period. Finally, EverSource Wealth Advisors LLC boosted its position in BioNTech by 106.3% in the first quarter. EverSource Wealth Advisors LLC now owns 489 shares of the company’s stock worth $43,000 after purchasing an additional 252 shares during the last quarter. 15.52% of the stock is owned by institutional investors.

BioNTech Price Performance

NASDAQ:BNTX opened at $111.77 on Monday. The business’s 50-day simple moving average is $104.56 and its two-hundred day simple moving average is $94.20. BioNTech SE has a 52 week low of $76.53 and a 52 week high of $131.49. The stock has a market cap of $26.57 billion, a PE ratio of 223.54 and a beta of 0.24. The company has a quick ratio of 7.40, a current ratio of 7.54 and a debt-to-equity ratio of 0.01.

BioNTech (NASDAQ:BNTX) last issued its earnings results on Monday, August 5th. The company reported ($3.36) earnings per share (EPS) for the quarter, missing the consensus estimate of ($2.02) by ($1.34). BioNTech had a negative net margin of 18.69% and a negative return on equity of 2.54%. The business had revenue of $128.70 million for the quarter, compared to the consensus estimate of $134.98 million. During the same period last year, the business posted ($0.86) EPS. The firm’s revenue for the quarter was down 23.3% compared to the same quarter last year. As a group, analysts forecast that BioNTech SE will post -3.04 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

Several equities analysts have recently weighed in on BNTX shares. HC Wainwright increased their price objective on shares of BioNTech from $113.00 to $150.00 and gave the stock a “buy” rating in a research note on Monday, October 7th. Bank of America upped their target price on shares of BioNTech from $125.00 to $150.00 and gave the company a “buy” rating in a report on Monday, September 16th. JPMorgan Chase & Co. upgraded shares of BioNTech from an “underweight” rating to a “neutral” rating and lifted their price target for the stock from $91.00 to $125.00 in a research note on Monday, September 16th. Jefferies Financial Group upgraded BioNTech from a “hold” rating to a “buy” rating and upped their price objective for the stock from $96.00 to $150.00 in a research note on Tuesday, September 17th. Finally, HSBC raised their target price on BioNTech from $97.00 to $136.00 and gave the stock a “buy” rating in a report on Monday, October 7th. Five research analysts have rated the stock with a hold rating, eight have issued a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat, the stock has an average rating of “Moderate Buy” and an average price target of $131.92.

BioNTech Profile

BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV 16+ head and neck cancers; BNT114 to treat triple negative breast cancer; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, which is in Phase I clinical trial for non-small cell lung cancer.